Sun Pharmaceutical Industries Limited has released the transcript of its Q2 FY26 earnings conference call. Financial Highlights (Consolidated Q2 FY26): * Sales stood at ₹144,052 million, marking an 8.6% growth year-on-year. * Gross margin was 79.3%. * EBITDA reached ₹45,271 million, an increase of 14.9% over Q2 FY25, with an EBITDA margin of 31.3%. * Net profit after tax was ₹31,180 million, up 2.6% year-on-year. * Earnings Per Share (EPS) was ₹13 per share. * Effective tax rate for the quarter was 24.7%. * The company reported a forex gain of ₹4,305 million. * Net cash position remained strong at $2.9 billion (approximately ₹24,147 crore), after accounting for the Checkpoint acquisition and GxMDL case settlement. Half-Yearly Performance (H1 FY26): * Sales were ₹281,913 million, growing 9.3% over H1 FY25. * Gross margin for the first half was 79.4%. * EBITDA for H1 was ₹88,287 million, a 17% growth, with a margin of 31.2%. * Adjusted net profit for H1 was ₹61,141 million, up 4.1%. Business Segment Highlights: * Global Innovative Medicines sales increased by 16.4% to $313 million (approximately ₹2,604 crore). For the first time, U.S. sales of Innovative Medicine surpassed generics. * ILUMYA is now commercialized in 35 major markets. * India Formulation sales grew by 11% to ₹47,348 million, contributing 32.9% to total consolidated sales. Sun Pharma is ranked number one in the Indian pharmaceutical market with an 8.3% share as per Pharmarack MAT September 2025, and launched 9 new products in India during the quarter. * Overall U.S. business declined by 4.1% to $496 million (approximately ₹4,124 crore), primarily due to increased competition for certain generic products and lower lenalidomide sales, which offset growth in Innovative Medicines (ILUMYA, CEQUA, ODOMZO). Three new generic products and LEQSELVI were launched in the U.S. during the quarter. * Emerging Markets formulation revenues were $325 million (approximately ₹2,702 crore), up 10.9% (8% in constant currency), driven by broad-based growth in Generics and Innovative Medicines. * Rest of the World formulation revenues were $234 million (approximately ₹1,946 crore), up 17.7%, with growth in both Generics and Innovative Medicines. R&D and Pipeline Updates: * Consolidated R&D investments for Q2 FY26 were ₹7,827 million, representing 5.4% of sales. * Innovative R&D accounted for 38% of total R&D spend. * The company is awaiting an FDA decision on UNLOXCYT's updated labeling and expects to launch UNLOXCYT in the U.S. in the second half of FY26. * Sun Pharma plans to file the ILUMYA psoriatic arthritis sBLA during the second half of FY26. Management Guidance and Commentary: * Full-year R&D spend is expected to be at the lower end of the 6%-8% guidance. * The GLP-1 market is considered exciting, and Sun Pharma aims to participate in India when patent expiries allow for generic entry. * The company confirmed its openness to considering further U.S. manufacturing presence. * Sales from generic lenalidomide are expected to be minimal for the remainder of the fiscal year, with the majority realized in the first half. * LEQSELVI's revenue contribution is anticipated to grow throughout the year as payer access improves. * ILUMYA for psoriasis is expected to continue its growth trajectory.
